跳至主要内容
临床试验/NCT06605378
NCT06605378招募中不适用

A Cross-Sectional, Observational Study of the Prevalence of Adenoviral-Specific Antibodies and Inflammatory Cytokines in Participants With Chronic Granulomatous Disease

Ensoma57 个研究点 分布在 2 个国家目标入组 60 人开始时间: 2024年11月18日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
60
试验地点
57
主要终点
Total adenoviral-specific antibody (TAb) titer

研究概览

简要总结

This research study is designed to assess the prevalence of specific antibodies and inflammatory cytokines in adult and pediatric participants with CGD.

详细描述

In this observational study, blood samples will be collected from adult and pediatric patients with CGD. The level of circulating adenovirus antibodies and inflammatory cytokines will be measured to characterize the prevalence of these markers in this population.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Cross Sectional

入排标准

性别
All
接受健康志愿者

入选标准

  • The participant must have been diagnosed with CGD based on the referring physician's confirmation that NADPH oxidase activity is ≤5% (i.e., the percentage of dihydrorhodamine-positive [DHR+] cells is ≤5% by flow cytometry) OR based on confirmed pathogenic mutation in a CGD associated gene (CYBB, CYBA, NCF1, NCF2, NCF4, or CYBC1).
  • The participant or the participant's legally authorized guardian or representative (if applicable) must be capable of giving signed informed consent.
  • The participant (with assistance from the participant's legally authorized guardian/representative or primary caregiver, if applicable) must be capable of complying with the requirements and restrictions listed in the protocol and informed consent form (ICF).

排除标准

  • The participant has undergone an allogeneic bone marrow transplant or investigational gene therapy.
  • The participant is unable to comply with the sample collection procedure based on investigator judgment.

结局指标

主要结局

Total adenoviral-specific antibody (TAb) titer

时间窗: 1 Day

Level of total adenoviral-specific antibody in blood

Adenoviral-specific neutralizing antibody (NAb) titer

时间窗: 1 Day

Level of adenoviral-specific neutralizing antibodies in blood

次要结局

  • Circulating inflammatory cytokine levels(1 Day)

研究者

发起方
Ensoma
申办方类型
Industry
责任方
Sponsor

研究点 (57)

Loading locations...

相似试验